Objective To investigate the clinical efficacy of low molecular weight heparin on community-acquired pneumonia (CAP). Methods A total of 78 patients with CAP admitted to hospital between January 2013 and March 2015 were randomly assigned into a conventional treatment group and a heparin treatment group. Both groups received anti-infection and symptomatic treatment, and the patients in heparin treatment group additionally received low molecular weight heparin by abdominal subcutaneous injection once daily for a course with seven days. The age, sex and severity of the disease were recorded. White blood cell (WBC) count and the levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured on and during admission. Results The baseline information including age and sex, severity of illness, CRP, ESR and WBC counts on admission and the first treatment day had no difference between two groups (P > 0.05). CRP and ESR on day 3 after treatment and WBC counts on day 7 after treatment in the heparin treatment group were significantly more decreased than those in the conventional treatment group (P < 0.05). For the moderate and severe CAP patients, the level of CRP on day 3 after treatment and WBC counts on day 7 after treatment in the heparin treatment group were significant lower than those in the conventional treatment group (P < 0.05). Conclusion Combination therapy of low molecular weight heparin may improve the clinical efficacy of CAP.

Citation： QiangLixia, LvNa, JinShoude. Clinical Efficacy of Low Molecular Weight Heparin on Community-acquired Pneumonia. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(4): 350-353. doi: 10.7507/1671-6205.2015087 Copy